PLEKHF2 - New-wiki

Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
L3MBTL3	L3MBTL histone methyl-lysine binding protein 3
LDOC1	LDOC1 regulator of NFKB signaling
MAGI2	membrane associated guanylate kinase, WW and PDZ domain containing 2	Nephrin family interactions
MAP2K1	mitogen-activated protein kinase kinase 1	MAPK3 (ERK1) activation Frs2-mediated activation Signal transduction by L1 Uptake and function of anthrax toxins RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway MAP3K8 (TPL2)-dependent MAPK1/3 activation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by MAP2K mutants Signaling by RAF1 mutants	K-252a 5-Bromo-N-[(2S)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide Cobimetinib Bosutinib (5S)-4,5-difluoro-6-[(2-fluoro-4-iodophenyl)imino]-N-(2-hydroxyethoxy)cyclohexa-1,3-diene-1-carboxamide 2-[(2-chloro-4-iodophenyl)amino]-N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluorobenzamide Mirdametinib N-(5-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-1,3,4-oxadiazol-2-yl)ethane-1,2-diamine 2-[(4-ETHYNYL-2-FLUOROPHENYL)AMINO]-3,4-DIFLUORO-N-(2-HYDROXYETHOXY)BENZAMIDE Trametinib Selumetinib Pimasertib	Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
MAX	MYC associated factor X	Transcription of E2F targets under negative control by DREAM complex Cyclin E associated events during G1/S transition Cyclin A:Cdk2-associated events at S phase entry Transcriptional Regulation by E2F6
MBIP	MAP3K12 binding inhibitory protein 1	HATs acetylate histones Formation of WDR5-containing histone-modifying complexes
MBP	myelin basic protein	EGR2 and SOX10-mediated initiation of Schwann cell myelination
MEAF6	MYST/Esa1 associated factor 6	HATs acetylate histones HATs acetylate histones Regulation of TP53 Activity through Acetylation
MFAP1	microfibril associated protein 1	mRNA Splicing - Major Pathway
MIDN	midnolin
MPP4	MAGUK p55 scaffold protein 4
MRI1	methylthioribose-1-phosphate isomerase 1	Methionine salvage pathway
NDUFA5	NADH:ubiquinone oxidoreductase subunit A5	Respiratory electron transport Complex I biogenesis RHOG GTPase cycle	NADH
NFIA	nuclear factor I A	RNA Polymerase III Transcription Termination RNA Polymerase III Abortive And Retractive Initiation
NONO	non-POU domain containing octamer binding
NPM2	nucleophosmin/nucleoplasmin 2	Replacement of protamines by nucleosomes in the male pronucleus
NSD2	nuclear receptor binding SET domain protein 2	PKMTs methylate histone lysines Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Nonhomologous End-Joining (NHEJ) Processing of DNA double-strand break ends G2/M DNA damage checkpoint		Multiple myeloma
NUDT2	nudix hydrolase 2	Detoxification of Reactive Oxygen Species
NUTM1	NUT midline carcinoma family member 1
P2RX7	purinergic receptor P2X 7	Elevation of cytosolic Ca2+ levels Platelet homeostasis The NLRP3 inflammasome The NLRP3 inflammasome Purinergic signaling in leishmaniasis infection Mechanical load activates signaling by PIEZO1 and integrins in osteocytes	Promethazine

Search Results for: PLEKHF2